CNBX Pharmaceuticals reported QQ3 2024 results characterized by a stark revenue scale-down and a substantial burn on operating activities. Revenue totaled $17.57 million for the quarter, with gross profit of $17.57 million and a reported gross margin of 100%, though the line item for cost of revenue is not disclosed, which obscures the true cost structure at this stage. The company posted a net loss of $131.0 million and EBITDA of $(152.0) million, driven by aggressive R&D and G&A spending (R&D $42.88 million; G&A $109.39 million) as CNBX continues to fund its cannabinoid-based discovery and development programs including RCC33 and other pipeline candidates. Operating loss was $(152.0) million, with an EBITDAR of $(8.65) million and an operating income margin of approximately (8.65)%.